key: cord-0802593-im8c9wy9
authors: Sharma, Aditi; Pant, Kumud; Pande, Akshara; Sinha, Somya; Pant, Bhasker
title: Modeling Novel Anti-Viral Peptides (AVPs) with in-silico Docking Simulations Against Corona Virus
date: 2021-02-27
journal: Mater Today Proc
DOI: 10.1016/j.matpr.2021.02.377
sha: e62fd3c27d672c1339d8b4fe3b0cfe0e762ffe6d
doc_id: 802593
cord_uid: im8c9wy9

The havoc created by Corona virus has been dealt with using various integrative approaches adopted by laboratories through-out the world. Use of anti-viral peptides (AVPs) although new but has shown tremendous potential against many pathogens. Previously AVPs have been designed against spike protein of corona virus which is the major entry mediating molecule. Using various in-silico strategies, in this research work AVPs have been modeled against lesser studied viral proteins namely ORF7a protein, Envelope protein (E), Nucleoprotein (N), and Non-Structural protein (Nsp1 and Nsp2). The predicted AVPs have been docked against various host as well as viral proteins. The interaction of small AVPs seems capable of interfering with binding between viral protein and its host counterpart. Therefore, these AVPs can act as a deterrent against novel corona virus, which requires further validation through laboratory techniques.

Corona virus (CoVs) has been known to be linked with significant disease outbreak in East Asia and the Middle East since past two decades. The pandemic of severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) has occurred during 2002 and 2012 respectively. Recently, in late 2019, emergence of a novel corona virus namely severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) has become the leading cause of corona virus disease 2019 (COVID-19) which has given rise to major health threat and an ongoing pandemic throughout the world [1] . Corona viruses are the member of Coronaviridae family (subfamily Coronavirinae), which causes infection in a wide range of hosts leading to symptoms and diseases like common cold and eventually fatal consequences such as SARS and MERS. Presently COVID-19, SARS-CoV-2 is believed to fall under one of the seven members of the corona virus family infecting humans; although, this novel virus is genetically different. There were only six CoVs until 2020 which were known to infect humans involving human CoV 229E (HCoV-229E), HCoV-NL63, HCoV-OC43, HCoV-HKU1, SARS-CoV, and MERS-CoV. Out of these, SARS-CoV and MERS-CoV have led to the major outbreaks with high mortality rates while others have been found to be linked with mild upper-respiratory-tract illness [2, 3] . As the evolution of this novel CoV-2 has caused a high public health threats worldwide, hence there is a great need to control this outbreak by utilizing various novel technologies like use of anti-virals, cell and gene therapies, immunomodulators, neutralizing antibodies and much more [4, 5] . Out of these, many recent evidences have been observed highlighting the functional properties of antiviral proteinaceous compounds as a defensive barrier and it has also been identified that some antimicrobial peptides can show their activity against a wide range of viruses, hence termed as antiviral peptides (AVPs) [6, 7, 8] .

These molecules when acquired by using bioinformatics tools are termed as designed or artificial AVPs which can be obtained through bait studies involving testing of an artificial peptide interacting against a specific target like a surface glycoprotein or a vital viral enzyme, it can also be derived using in-silico approach by utilizing specific software that are designed to predict peptides [9, 10, 11] . There are various advantages associated with the utilization of antiviral peptides including inhibition of protein-protein interactions, an alternative against diseases which are difficult to target, availability of advance technologies that will enhance peptide half-life and shorter market time [12] . Along with various advantages, there are certain side effects related with peptide drugs and minute drug tolerance in comparison to chemical drugs. Meanwhile, the peptide based treatment is highly specific, besides this there is a need of special storage circumstances for peptide drugs in order to avoid inactivation of protein functions leading to low oral bioavailability and the tendency of rapid metabolism [13] .

Therefore the need for novel therapeutics in the form of AVPs against essential viral proteins, as a boost in the research against the same, cannot be denied. Previously anti-viral peptides have been designed against fusion protein and spike protein of corona virus [14, 15] . Moreover the use of anti-viral peptides against SARS-CoV2, SARS-CoV, MERS-CoV, SARS-related CoVs, and other respiratory viruses has been documented [16] .

Realizing the therapeutic potential of these peptides, in this research work the lesser explored proteins of CoV-2 as novel drug targets have been used for designing AVPs. The proteins include ORF7a, Envelope protein (E), Nucleoprotein (N), Nsp1 and Nsp2. The ORF7a protein of Severe acute respiratory syndrome corona virus 2 (2019-nCov) has been found located in the host endoplasmic reticulum membrane, host endoplasmic reticulum-Golgi intermediate compartment membrane and host Golgi apparatus membrane. Its length is 121 with molecular weight 13.744 Da and interacts with the spike glycoprotein, M protein, E protein, ORF3a protein, human SGT, host ITGAL and host BST2. It takes part in biological process like modulating viral host G0/G1 transition checkpoint, suppressing viral host Tetherin activity and suppressing viral host type I interferon-mediated signaling pathway. It functions as an antagonist of host Tetherin (BST2), by binding to BST2 thereby interfering with its glycosylation and in-turn disrupting its antiviral effect along with this, it may also suppress siRNA and may bind to host ITGAL, thereby playing a role in attaching and modulating leukocytes. Envelope protein (E) of SARS-CoV-2 has a major role in viral morphogenesis and assembly but the short length of the protein lessens the probability of finding AVPs In this research paper an attempt has been made to piece-together novel AVPs against the mentioned target viral as well as host proteins using various in-silico resources. The confirmation of anti-viral activity through further laboratory experimentation could be a major boost in fighting against ever invading microorganisms with the proof that 'solution to the problem lies within the problem itself'.

ViralZone has been used for retrieving information on corona virus intearactome [20] . From the interactome, proteins other than spike have been considered for predicting AVPs. The significant server cum databases for prediction, analysis and storage of AVPs are AVPpred [21] , APD3 [22] , CAMPR3 [23] and HIPdb [24] . AVPpred is the first database and server developed using peptides with experimentally proven antiviral activity with implementation done using machine learning models, therefore has been chosen for analysis and prediction.

Profile ALIgNEment (PRALINE), a flexible multiple sequence alignment tool, is another software to be used in this research work. It has numerous advantages besides having user friendly interface and easily interpretable output [25, 26] . The software has been applied for multiple sequence alignment of target viral protein so as to select most conserved stretch of residues to be tested further as anti-viral peptide.

The predicted anti-viral peptide(s) are docked or checked for the interaction ability with host and viral protein using publicly available servers. For peptide-protein docking or interaction prediction and ab-initio docking algorithm based tool MDockPeP has been used. This server docks all-atom, flexible peptide to receptor and later docked poses are ranked based on statistical potential-based scoring function, ITScorePeP [27, 28] .

Another downloadable software iGemDock, a virtual screening tool with facility for post screening analysis, has been used for predicting interaction analysis of viral non-spike proteins with predicted AVPs [29] . LIGPLOT+ downloadable servers have been used for analysis of interacting residues between receptor and ligands [30, 31] . This server allows observation of all kind of bonds as well as interacting residues between modeled peptide and host protein.

The CASTp (Computed Atlas of Surface Topography of proteins) server at http://sts.bioe.uic.edu/castp/ is used for predicting pockets and also cavities on protein on which ligands can bind [32] .

The various servers and software as mentioned above have been used for prediction of novel AVPs through analysis performed at various levels against major virulent proteins of Corona virus.

The strategy of finding anti-viral peptide as a deterrent has been previously explored for spike protein of the virus by Torres Jesús et al. [33] . Therefore, the lesser explored viral proteins have been considered for designing anti-viral peptides and are tabulated in table 1. In the preliminary step PODTC7 homologs were aligned through PRALINE on-line server. The homologues with more than 80% similarity were included as a part of analysis. For analysis of peptides with antiviral potential, multiple sequence alignment was performed to find the most conserved residues. These residues were predicted to have very important role on interaction with host protein. The residues were investigated for their anti-viral property using AVPred server accessible at http://crdd.osdd.net/servers/avppred/ [21] . Only one conserved sequence was found to have AVP with good probability (KLFIRQEE). Its various physiochemical properties are shown in figure 1 . The amphiphilic character of peptides and overall hydrophobicity is responsible for anti-viral characteristics. As can be seen in figure 1 although the hydrophobicity value of predicted AVP is lesser but other characteristics like surface exposed residues, disorder promotion and flexibility may be good enough for peptide to have anti-viral properties. The presence of conserved amino acids as predicted through PRALINE server for PODTC7 is shown in figure 2 [25, 26] . Majority of the aligned portion is found to have good conservancy score. Therefore to reveal the most suitable amino acid residue fragment the entire sequence was checked for anti-viral properties in sliding window of 1 through AVPred server. The physiochemical properties of the predicted AVP are exhibited in figure 3.

In figure 3 the variation in hydrophobicity throughout the peptide is shown in green line along Y axis. The frequency of alpha helix seems to be on an increasing trend which is again a prerequisite for effective anti-viral activity of a peptide. The similar variation in properties for other predicted peptide is indicative of effect of varying amino acid composition on anti-viral property. The predicted anti-viral peptides have been tested for binding ability with both host as well as viral proteins. The various viral proteins are mentioned in table 3. The 3D structure of viral proteins has been obtained from Protein Data Bank (PDB) databank. For nucleoprotein two structures with ID 6M3M and 6WZO were considered for analysis since they represent different region of the big nucleoprotein. Similar is the case with replicase polyprotein 1a where two PDB IDs are analyzed for predicting binding interactions. The choice of viral proteins has been expanded so as to uncover the region binding best with the predicted AVPs and with the best resolution.

The interaction or docking of predicted AVPs (from table 2) with host target protein (shown in table 1), has been done with MDockPeP server. The interacting energies are shown in table 4. The energies are result of cumulative effect of weak interactions between peptide and host proteins. Only the top scoring models or the models with best docking score are tabulated. The best interactions are thermodynamically most favored one. The more is the energy dissipated or released stronger or better is the interaction.

2) is done through iGemDock software and depicted through LigPLOT, one has been shown in figure 6 [29] [30] [31] . The same has been generated for rest of the proteins also. The interacting energies are summarized in table 5. From table 5 it is found that envelope small membrane protein interacts best with predicted anti-viral peptide out of all viral proteins.

In figure 7 the pocket forming residues or active site residues of various host proteins are depicted. The prediction is made through CASTp server which signifies the amino acid residues that are a part of active site (32) . The AVPs designed through in-silico approach have been found to bind with important residues of protein, mentioned in table 1 and table 3 and also predicted through CASTp shown in table 6. The effect of predicted AVPs in blocking the active site residues has been studied in conjunction with the amino acid residues involved in pocket or cavity prediction for various receptor proteins that are mentioned in table 1 and 3.

The designed AVPs show optimum binding with both host as well as viral proteins. This binding can prevent the viral protein from binding to natural target of host protein. The bound peptide fragments to viral nonspike proteins can block the viral proteins from functioning properly therefore acting as anti-viral agents. 

In this research work anti-viral peptides or AVPs have been designed using computational approach against proteins other than spike of Corona virus. The designed AVPs are tested for their ability to prevent binding of pathogen proteins with host proteins. In principle deterrent proteins can be designed both against host and pathogen.

The same principle has been tested here with binding induced between host and viral proteins and predicted AVPs.

The AVPs in-fact can block the active sites of host as well as pathogen thereby preventing further activities.

The disruption caused at various levels by the effect of global COVID-19 outbreak has prioritized the immediate and urgent treatment therapies. In this concern, we believe that the production of AVPs could represent the most promising treatment strategy. In our study, the AVPs designed through in-silico approach have been found to bind with important residues of protein mentioned in table 1 and 3. This binding can prevent the viral protein from binding to natural target of host protein, therefore acting as anti-viral agents. AVPs being simple with its primary structure and versatile functional properties may prove to be potential candidate in facing COVID-19 and several other emerging outbreaks in unpredictable future. We have explored the in-silico facet of AVPs prediction providing basis for its in-vitro analysis. Still there are certain aspects involving their potential utilization in clinical treatment and promising antiviral activity along with studying prophylactic reactions concerned against COVID-19

which are needed to be investigated in near future.

History is repeating itself probable zoonotic spillover as the cause of the 2019 novel corona virus epidemic

Novel Corona virus Investigating and Research Team. A novel corona virus from patients with pneumonia in China

Evolutionary perspectives on novel corona viruses identified in pneumonia cases in China

A novel corona virus emerging in Chinakey questions for impact assessment

Dual antiviral activity of human alpha-defensin-1 against viral haemorrhagic septicaemia rhabdovirus (VHSV) Inactivation of virus particles and in-duction of a type I interferon-related response

Human antimicrobial peptides LL-37 and human βdefensin-2 reduce viral replication in keratinocytes infected with varicella zoster virus

Antiviral activity of the EB peptide against zoonotic poxviruses

A synthetic peptide from a heptad repeat region of herpesvirus glycoprotein B inhibits virus replication

Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo

Towards the improved discovery and design of functional peptides: common features of diverse classes permit generalized prediction of bioactivity

Future directions for peptide therapeutics development

Basics and recent advances in peptide and protein drug delivery

In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2

Fusion Protein Targeted Antiviral Peptides: Fragment-Based Drug Design (FBDD) Guided Rational Design of Dipeptides Against SARS-CoV2

The Potential of Antiviral Peptides as COVID-19 Therapeutics

ViralZone: a knowledge resource to understand virus diversity

AVPpred: collection and prediction of highly effective antiviral peptides

APD3: The antimicrobial peptide database as a tool for research and educa-tion

CAMPR3: a database on sequences, structures and signatures of antimicrobial peptides

HIPdb: a database of experimentally validated HIV inhibiting pep-tides

Two strategies for sequence comparison: profile-preprocessed and secondary structure-induced multiple alignment

Local weighting schemes for protein multiple sequence alignment

MDockPeP: An ab-initio protein-peptide docking server

Fully Blind Docking at the Atomic Level for Protein-Peptide Complex Structure Prediction

iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis

The Protein Data Bank

Multiple Ligand-Protein Interaction Diagrams for Drug Discovery

CASTp 3.0: computed atlas of surface topography of pro-teins

Prediction of antiviral peptides derived from viral fusion proteins potentially active against herpes simplex and influenza A viruses

The authors are highly thankful to Graphic Era Deemed to be University, Dehradun, Uttarakhand, Department of Biotechnology for providing facility to carry out this work.

 Anti-viral peptides designed in-silico against non-spike proteins of Corona Virus  Docking simulations against both host and viral proteins  Good binding efficiency observed in between modeled peptide and viral membrane protein  Novel deterrent against corona virus.  Act by binding to the active site or ligand binding site of the target protein thereby preventing further activity and binding of target protein with natural binders. We wish to draw the attention of the Editor to the following facts, which may be considered as potential conflicts of interest, and to significant financial contributions to this work:

The nature of potential conflict of interest is described below: None

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

Funding was received for this work.All of the sources of funding for the work described in this publication are acknowledged below:

√No funding was received for this work.

√ We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

The International Committee of Medical Journal Editors (ICMJE) recommends that authorship be based on the following four criteria:1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND 2. Drafting the work or revising it critically for important intellectual content; AND 3. Final approval of the version to be published; AND 4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. For more information on authorship, please see http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authorsand-contributors.html#two.√All listed authors meet the ICMJE criteria. We attest that all authors contributed significantly to the creation of this manuscript, each having fulfilled criteria as established by the ICMJE.We believe these individuals should be listed as authors because:

All have contributed significantly in the paper √We confirm that the manuscript has been read and approved by all named authors.√We confirm that the order of authors listed in the manuscript has been approved by all named authors.

The Corresponding Author declared on the title page of the manuscript is:

√This author submitted this manuscript using his/her account in EVISE.

√We confirm that the email address shown below is accessible by the Corresponding Author, is the address to which Corresponding Author's EVISE account is linked, and has been configured to accept email from the editorial office of American Journal of Ophthalmology Case Reports:

Someone other than the Corresponding Author declared above submitted this manuscript from his/her account in EVISE:

We understand that this author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors, including the Corresponding Author, about progress, submissions of revisions and final approval of proofs.We the undersigned agree with all of the above.